Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation

Annals of Clinical and Translational Neurology

Volumn 2, Issue 2, 2015, Pages 151-166

  Homma, Sachiko ^a   Beermann, Mary Lou ^a   Boyce, Frederick M ^b   Miller, Jeffrey Boone ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD56 ANTIGEN; DUX4 FL PROTEIN; PEPTIDES AND PROTEINS; TAR DNA BINDING PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRIFUGATION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; DUX4 FL GENE; ENZYME ACTIVITY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HEK293 CELL LINE; HEP-2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUSCLE BIOPSY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN HOMEOSTASIS; TARDBP GENE; UBIQUITINATION;

EID: 84958170812     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.158     Document Type: Article

References (68)

1. Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010;329:1650–1653.
2. Snider L, Geng LN, Lemmers RJ, et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet 2010;6:e1001181.
3. Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet Muscle 2014;4:12.
4. Tawil R. Facioscapulohumeral muscular dystrophy. Neurotherapeutics 2008;5:601–606.
5. Cabianca DS, Gabellini D. The cell biology of disease: FSHD: copy number variations on the theme of muscular dystrophy. J Cell Biol 2010;191:1049–1060.
6. van der Maarel SM, Tawil R, Tapscott SJ. Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med 2010;17:252–258.
7. Scionti I, Greco F, Ricci G, et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am J Hum Genet 2012;90:628–635.
8. Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012;44:1370–1374.
9. van der Maarel SM, Miller DG, Tawil R, et al. Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation. Curr Opin Neurol 2010;25:614–620.
10. Hartweck LM, Anderson LJ, Lemmers RJ, et al. A focal domain of extreme demethylation within D4Z4 in FSHD2. Neurology 2013;80:392–399.
11. Gaillard MC, Roche S, Dion C, et al. Differential DNA methylation of the D4Z4 repeat in patients with FSHD and asymptomatic carriers. Neurology 2014;83:733–742.
12. Kowaljow V, Marcowycz A, Ansseau E, et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord 2007;17:611–623.
13. Bosnakovski D, Xu Z, Gang EJ, et al. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J 2008;27:2766–2779.
14. Wuebbles RD, Long SW, Hanel ML, Jones PL. Testing the effects of FSHD candidate gene expression in vertebrate muscle development. Int J Clin Exp Pathol 2010;3:386–400.
15. Mitsuhashi H, Mitsuhashi S, Lynn-Jones T, et al. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy. Hum Mol Genet 2013;22:568–577.
16. Geng LN, Yao Z, Snider L, et al. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell 2010;22:38–51.
17. Jones TI, Chen JCJ, Rahimov F, et al. DUX4-fl expression in both FSHD subjects and unaffected relatives provides evidence for modifiers and a quantitative model of pathogenesis. Hum Mol Genet 2010;21:4419–4430.
18. Block GJ, Narayanan D, Amell AM, et al. Wnt/β-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells. Hum Mol Genet 2013;22:4661–4672.
19. Cohen TJ, Lee VM, Trojanowski JQ. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med 2011;17:659–667.
20. Greenberg SA. Inclusion body myositis. Curr Opin Rheumatol 2011;23:574–578.
21. Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat 2013;34:812–826.
22. Homma S, Chen JCJ, Rahimov F, et al. A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease, & cell function. Eur J Hum Genet 2012;20:404–410.
23. Himeda C, Debarnot C, Homma S, et al. Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy associated DUX4 gene. Mol Cell Biol 2014;34:1942–1955.
24. Geng LN, Tyler AE, Tapscott SJ. Immunodetection of human double homeobox 4. Hybridoma (Larchmt) 2011;30:125–130.
25. Nonaka T, Kametani F, Arai T, et al. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet 2009;18:524–530.
26. Hishiya A, Iemura S, Natsume T, et al. A novel ubiquitin-binding protein ZNF216 functioning in muscle atrophy. EMBO J 2006;25:554–564.
27. Boyce FM, Bucher NL. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci USA 1996;93:2348–2352.
28. Luckow VA, Lee SC, Barry GF, Olins PO. Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. J Virol 1993;67:4566–4579.
29. Sassone J, Ciammola A, Tiloca C, et al. Apoptosis induced by proteasome inhibition in human myoblast cultures. Eur J Histochem 2006;50:109–118.
30. Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy. Neurosci Lett 1991;130:73–76.
31. Küsters B, van Hoeve BJ, Schelhaas HJ, et al. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol 2009;117:209–211.
32. Vanderplanck C, Ansseau E, Charron S, et al. The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One 2011;6:e26820.
33. Kastle M, Grune T. Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal system. Curr Pharm Des 2011;17:4007–4022.
34. Tassin A, Laoudj-Chenivesse D, Vanderplanck C, et al. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy? J Cell Mol Med 2013;17:76–89.
35. Weihl CC, Pestronk A. Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Curr Opin Neurol 2010;23:482–488.
36. Dubourg O, Wanschitz J, Maisonobe T, et al. Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. Acta Myol 2011;30:103–108.
37. Arnold ES, Ling SC, Huelga SC, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci USA 2013;110:E736–E745.
38. Udan-Johns M, Bengoechea R, Bell S, et al. Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. Hum Mol Genet 2014;23:157–170.
39. Spletter ML, Schnorrer F. Transcriptional regulation and alternative splicing cooperate in muscle fiber-type specification in flies and mammals. Exp Cell Res 2014;321:90–98.
40. Pistoni M, Ghigna C, Gabellini D. Alternative splicing and muscular dystrophy. RNA Biol 2010;7:441–452.
41. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001;292:1552–1555.
42. Tydlacka S, Wang CE, Wang X, et al. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci 2008;28:13285–13295.
43. van Eersel J, Ke YD, Gladbach A, et al. Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS One 2011;6:e22850.
44. Chang HY, Hou SC, Way TD, et al. Heat-shock protein dysregulation is associated with functional and pathological TDP-43 aggregation. Nat Commun 2013;4:2757.
45. Huang CC, Bose JK, Majumder P, et al. Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. J Cell Sci 2014;127:3024–3038.
46. Wallace LM, Garwick SE, Mei W, et al. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann Neurol 2011;69:540–552.
47. Yao Z, Snider L, Balog J, et al. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle. Hum Mol Genet 2014;23:5342–5352.
48. Cabianca DS, Casa V, Bodega B, et al. A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. Cell 2012;149:819–831.
49. Dmitriev P, Stankevicins L, Ansseau E, et al. Defective regulation of microRNA target genes in myoblasts from facioscapulohumeral dystrophy patients. J Biol Chem 2013;288:34989–35002.
50. Harafuji N, Schneiderat P, Walter MC, Chen YW. miR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors. Orphanet J Rare Dis 2013;8:55.
51. Charrin S, Latil M, Soave S, et al. Normal muscle regeneration requires tight control of muscle cell fusion by tetraspanins CD9 and CD81. Nat Commun 2013;4:1674.
52. Ferreboeuf M, Mariot V, Furling D, et al. Nuclear protein spreading: implication for pathophysiology of neuromuscular diseases. Hum Mol Genet 2014;23:4125–4133.
53. Dixit M, Ansseau E, Tassin A, et al. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci USA 2007;104:18157–18162.
54. Pandey SN, Cabotage J, Shi R, et al. Conditional over-expression of PITX1 causes skeletal muscle dystrophy in mice. Biol Open 2012;1:629–639.
55. Turki A, Hayot M, Carnac G, et al. Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction. Free Radic Biol Med 2012;53:1068–1079.
56. Bosnakovski D, Choi SH, Strasser JM, et al. High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity. Skelet Muscle 2014;4:4.
57. Höhn TJ, Grune T. The proteasome and the degradation of oxidized proteins: part III-Redox regulation of the proteasomal system. Redox Biol 2014;2:388–394.
58. Segref A, Kevei E, Pokrzywa W, et al. Pathogenesis of human mitochondrial diseases is modulated by reduced activity of the ubiquitin/proteasome system. Cell Metab 2014;19:642–652.
59. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 2013;79:416–438.
60. Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta 2014;1843:13–25.
61. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351:602–611.
62. Olivé M, Janué A, Moreno D, et al. TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009;68:262–273.
63. von Mikecz A. The nuclear ubiquitin-proteasome system. J Cell Sci 2006;119:1977–1984.
64. Askanas V, Engel WK, Nogalska A. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol 2012;71:680–693.
65. Kim HJ, Raphael AR, LaDow ES, et al. Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet 2014;46:152–160.
66. Gendron TF, Petrucelli L. Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. J Mol Neurosci 2011;45:486–499.
67. Yang C, Wang H, Qiao T, et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2014;111:E1121–E1129.
68. Wallace LM, Liu J, Domire JS, et al. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. Mol Ther 2012;20:1417–1423.